Stem cell transplant findings could lead to personalised type 1 diabetes treatments

A clinical trial has shown promising findings from stem cell transplants in people with type 1 diabetes, with some patients coming off insulin injections for several years.

This international research could also lead to better outcomes for more patients who undergo stem cell transplantation, according to senior author Dr Bart Roep, City of Hope and director of the Wanek Family Project for Type 1 Diabetes.

“This study paves the way for personalised therapy in type 1 diabetes,” Roep said. “We now understand stem cell transplants can succeed in treating diabetes for some, but not in others, and we can predict either outcome before the therapy is administered by ‘reading’ the immune signature of the patient.”

Roep and colleagues were testing a type of stem cell transplantation called autologous hematopoietic stem cell transplantation (AHSCT).

This involves a person’s own stem cells being transplanted with researchers able to see how much insulin is then made by the pancreas.

The researchers’ aim was for the procedure to induce insulin independence in participants, and understand why some patients can achieve long-term clinical benefits from stem cell transplantation and others cannot.

Twenty-one participants with type 1 diabetes received this transplantation in Brazil. They were then monitored and assessed every six months.

Most patients were able to come off insulin for an average of 3.5 years, while one patient was free of insulin for more than eight years after transplantation, without any major side effects.

Roep added that some participants received little to no benefit from transplantation. “However, we discovered the immune signature predicting these outcomes – either favourable or not – which is the first step towards personalised medicine in type 1 diabetes. We have a foot in the door,” he said.

For the full article, click here.


stem cell preservation

BSc (Hons) Microbiology

Chief Executive Officer | Biovault Family

Biovault Family CEO, Kate Sneddon, joined Biovault in July 2009 and became Chief Executive Officer in 2016. As health industry professional her experience includes working as a microbiologist and leader at GSK for over 10 years. Her expertise in cord blood banking has been recognised in her awards, features in Parliamentary Review and Parents Guide to Cord Blood, as well as contributions to research with UCL and others.

Share This Article:



Request a Brochure

Find out more.

Our hope is that the information in this brochure will empower you as you weigh-up your cord blood and tissue storage options and prepare for your family’s healthy future.

Download your free guide to Biovault Family's cord blood banking!